Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Walmart marks down popular pandemic goods due to excess inventory

    August 7, 2022

    Starbucks CFO talks earnings, iced drinks, and unionization

    August 7, 2022

    Volume Breakout Report: August 6, 2022 (Technical Analysis)

    August 7, 2022
    Facebook Twitter Instagram YouTube LinkedIn RSS
    Facebook Twitter Instagram YouTube LinkedIn
    MB3 Network MB3 Network
    Subscribe Login
    • Home
    • Business Market
      • General Market News
      • Conference
      • Press Release
      • Articles
      • Lay offs
      • Technical Analysis
      • Consumer Goods
    • Crypto Currency
      • Crypto News
      • Positive
      • Technical Analysis
      • Mining
      • Digital Yuan
      • Stable Coins
      • Institutions
      • Regulations
      • Libra/Diem
      • Upgrades
      • NFT
    • 2022 IPO
    • Technology
    MB3 Network MB3 Network
    Home»Press Releases»Ascletis Announces Completion of the Bridging Study and Initiation of Phase II Trial of FXR Agonist ASC42 in China for Chronic Hepatitis B Indication
    Press Releases

    Ascletis Announces Completion of the Bridging Study and Initiation of Phase II Trial of FXR Agonist ASC42 in China for Chronic Hepatitis B Indication

    userBy userAugust 25, 2021Updated:September 23, 2021No Comments1 Min Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    –ASC42 bridging study demonstrated consistent pharmacokinetic profiles between U.S. and Chinese population — ASC42 was safe and well tolerated in Chinese population with only grade 1 adverse events –10 mg and 15 mg once daily doses of ASC42 were selected in combination with pegylated interferon and nucleos(t)ide analogs for Phase II study in patients with chronic hepatitis B HANGZHOU and SHAOXING, China, Aug. 24, 2021 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672) announces today the completion of the bridging study and initiation of Phase II trial of farnesoid X receptor (FXR) agonist ASC42 in China for chronic hepatitis B (CHB) indication. ASC42 is an in-house developed, novel non-steroidal, selective, potent FXR agonist with best-in-class potential.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleBLCT INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BlueCity Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline Securities Class Action – BLCT
    Next Article Urban Outfitters, Inc.’s (URBN) CEO Richard Hayne on Q2 2022 Results – Earnings Call Transcript
    user
    • Website

    Related Posts

    AMGEN DATA AT WCLC 2022 HIGHLIGHTS POTENTIAL TO DELIVER TRANSFORMATIVE MEDICINES FOR HISTORICALLY DIFFICULT-TO-TREAT LUNG CANCERS

    August 7, 2022

    Foremost Lithium Announces First Anniversary Option Payment for the Jean Lake Lithium-Gold Property Snow Lake, Manitoba

    August 7, 2022

    WM FINAL DEADLINE TOMORROW: ROSEN, A TOP RANKED FIRM, Encourages Waste Management, Inc. Investors to Secure Counsel Before Important August 8 Deadline in Securities Class Action – WM

    August 7, 2022

    EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lung Cancer

    August 7, 2022

    Leave A Reply Cancel Reply

    Recent Posts
    • Walmart marks down popular pandemic goods due to excess inventory
    • Starbucks CFO talks earnings, iced drinks, and unionization
    • Volume Breakout Report: August 6, 2022 (Technical Analysis)
    • SPY: Our $416 Buy Alert (Technical Analysis)
    • Nine Energy Service, Inc. (NINE) CEO Ann Fox on Q2 2022 Results – Earnings Call Transcript
    Recent Comments
      Search
      Banner
      Newsletter

      Whoops, you're not connected to Mailchimp. You need to enter a valid Mailchimp API key.

      Tags
      culture featured leisure Lifestyle (Demo) picks spotlight tech
      Banner
      Archives
      • August 2022 (626)
      • July 2022 (2467)
      • June 2022 (2464)
      • May 2022 (2612)
      • April 2022 (1158)
      • November 2021 (10)
      • October 2021 (39)
      • August 2021 (700)
      • January 2021 (50)
      Banner
      Banner
      Archives
      • August 2022
      • July 2022
      • June 2022
      • May 2022
      • April 2022
      • November 2021
      • October 2021
      • August 2021
      • January 2021
      Archives
      • August 2022
      • July 2022
      • June 2022
      • May 2022
      • April 2022
      • November 2021
      • October 2021
      • August 2021
      • January 2021
      Meta
      • Log in
      • Entries feed
      • Comments feed
      • WordPress.org
      Categories
      • Politics
      • World
      • Tech & Science
      • Business
      Demo
      Our Picks

      Remember! Bad Habits That Make a Big Impact on Your Lifestyle

      January 13, 2021

      The Right Morning Routine Can Keep You Energized & Happy

      January 13, 2021

      How to Make Perfume Last Longer Than Before

      January 13, 2021

      Stay off Social Media and Still Keep an Online Social Life

      January 13, 2021
      • Facebook
      • Twitter
      • Pinterest
      • Instagram
      • YouTube
      • Vimeo
      Don't Miss
      Videos

      Walmart marks down popular pandemic goods due to excess inventory

      By userAugust 7, 20220

      Walmart stocked up its stores initially when the pandemic began. Now, Walmart is reducing its…

      Starbucks CFO talks earnings, iced drinks, and unionization

      August 7, 2022

      Volume Breakout Report: August 6, 2022 (Technical Analysis)

      August 7, 2022

      SPY: Our $416 Buy Alert (Technical Analysis)

      August 7, 2022

      Subscribe to Updates

      Get the latest creative news from SmartMag about art & design.

      Connect today to share and discuss business concepts, investment ideas and money related topics with success driven people.

      Email Us




        Flickr Photos
        Skype_Picture_2021_08_22T08_53_38_471Z
        Skype_Picture_2021_08_22T08_53_42_576Z
        Skype_Picture_2021_08_22T08_53_56_455Z
        Skype_Picture_2021_08_22T08_53_59_302Z
        Skype_Picture_2021_08_12T09_52_54_053Z (1)
        Skype_Picture_2021_08_22T08_53_34_626Z
        Skype_Picture_2021_08_22T08_53_30_802Z
        Skype_Picture_2021_08_22T08_53_25_722Z
        Skype_Picture_2021_08_22T08_53_21_947Z
        Facebook Twitter Instagram YouTube LinkedIn
        • Home
        • Politics
        • Business
        • Technology
        • Buy Now
        © 2022 MB3 News

        Type above and press Enter to search. Press Esc to cancel.

        Sign In or Register

        Welcome Back!

        Login to your account below.

        Lost password?